UCP2 expression may represent a predictive marker of neoadjuvant chemotherapy effectiveness for locally advanced uterine cervical cancer.

Concurrent chemoradiotherapy is the standard treatment for locally advanced uterine cervical cancer. However, effective neoadjuvant chemotherapy (NAC) can reduce tumor size and facilitate hysterectomy for locally advanced uterine cervical cancer. NAC treatment could improve the prognosis of patients with locally advanced cervical cancer. However, if NAC is ineffective, radiotherapy must be pursued. This causes a delay in initiating the core treatment and results in a worse prognosis. Therefore, the identification of predictive markers of whether NAC is likely to be effective for the treatment of locally advanced uterine cervical cancer could improve patient prognosis. Uncoupling protein 2 (UCP2) is broadly expressed in cancer cells, and suppresses mitochondrial reactive oxygen species (ROS) production. UCP2 contributes to both carcinogenesis and chemoresistance by reducing ROS. Downregulation of UCP2 results in significantly increased cell death following chemotherapy. The present study investigated the association between UCP2 expression and NAC effectiveness. A total of 58 patients with locally advanced uterine cervical cancer (stage IIIA or IIIB) treated at Osaka City University Hospital between April 1995 and March 2010 were examined. Tumor tissue samples were obtained by punch biopsy prior to NAC. UCP2 expression was examined immunohistochemically and scored using a weighted scoring system. Patients were divided into NAC effective (n=34) and ineffective (n=24) groups. Furthermore, UCP2 expression in human uterine cervical cancer cells was inhibited by genipin, and changes in cisplatin sensitivity were examined. UCP2 weighted score was higher in the NAC ineffective group than in the NAC effective group (P=0.038). Additionally, the low UCP2 expression group was more sensitive to NAC than the high UCP2 expression group (P=0.041). Sensitivity to cisplatin was significantly increased when UCP2 was inhibited in human uterine cervical cancer cells in vitro. UCP2 expression may become a predictive marker of whether NAC is effective for patients with locally advanced uterine cervical cancer, which could improve patient prognosis.

[1]  Tsuyoshi Saito,et al.  Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer , 2015, International Journal of Clinical Oncology.

[2]  M. Donadelli,et al.  Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. , 2012, Biochimica et biophysica acta.

[3]  Matthew D. Smith,et al.  Toward understanding the mechanism of ion transport activity of neuronal uncoupling proteins UCP2, UCP4, and UCP5. , 2012, Biochemistry.

[4]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[5]  M. Harper,et al.  Genipin-Induced Inhibition of Uncoupling Protein-2 Sensitizes Drug-Resistant Cancer Cells to Cytotoxic Agents , 2010, PloS one.

[6]  G. Baffy.  Uncoupling protein-2 and cancer. , 2010, Mitochondrion.

[7]  S. Pecorelli.  Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[8]  R. Angioli,et al.  Neoadjuvant Chemotherapy Followed by Radical Surgery in Patients Affected by FIGO Stage IVA Cervical Cancer , 2007, Annals of Surgical Oncology.

[9]  F. Meyskens,et al.  UC Irvine UC Irvine Previously Published Works Title Reactive oxygen species : a breath of life or death ? , 2007 .

[10]  F. Goldwasser,et al.  Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel‐induced cancer cell death both in vitro and in vivo , 2006, International journal of cancer.

[11]  J. Wands,et al.  Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. , 2006, Carcinogenesis.

[12]  Catherine Jones,et al.  Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[13]  O. Ishiko,et al.  Expression of apoptosis-related proteins in advanced uterine cervical cancer after balloon-occluded arterial infusion chemotherapy as an indicator of the efficiency of this therapy. , 2005, International journal of molecular medicine.

[14]  O. Ishiko,et al.  Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer. , 2004, International journal of molecular medicine.

[15]  J. Wands,et al.  Expression of Uncoupling Protein-2 in Human Colon Cancer , 2004, Clinical Cancer Research.

[16]  Peng Huang,et al.  ROS stress in cancer cells and therapeutic implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[17]  Mitchell Morris,et al.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Steven P Jones,et al.  Uncoupling Protein-2 Overexpression Inhibits Mitochondrial Death Pathway in Cardiomyocytes , 2003, Circulation research.

[19]  G. Tomasevic,et al.  Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma , 2003, Nature Medicine.

[20]  Robin A. J. Smith,et al.  Superoxide Activates Mitochondrial Uncoupling Protein 2 from the Matrix Side , 2002, The Journal of Biological Chemistry.

[21]  A. Nègre-Salvayre,et al.  Increased reactive oxygen species production with antisense oligonucleotides directed against uncoupling protein 2 in murine endothelial cells. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[22]  O. Ishiko,et al.  Expression of apoptosis regulatory proteins in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion chemotherapy. , 2001, International journal of oncology.

[23]  K. Nakamura,et al.  Tumor marker and MR imaging criteria for evaluating the efficacy of cyclic balloon-occluded arterial infusion for advanced cancer of the uterine cervix. , 2000, Oncology reports.

[24]  K. Nakamura,et al.  Balloon-occluded arterial infusion chemotherapy, simple total hysterectomy, and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervix. , 2000, Oncology reports.

[25]  D. Sanchís,et al.  The mitochondrial uncoupling protein-2: current status. , 1999, The international journal of biochemistry & cell biology.

[26]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[27]  J. Prieto,et al.  Transformed but not normal hepatocytes express UCP2 , 1998, FEBS letters.

[28]  O. Boss,et al.  The uncoupling proteins, a review. , 1998, European journal of endocrinology.

[29]  R. Yamada,et al.  Effect of balloon occluded arterial infusion of anticancer drugs on the prognosis of cervical cancer treated with radiation therapy. , 1995, International journal of radiation oncology, biology, physics.

[30]  M. Yen,et al.  Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Lee,et al.  bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. , 1995, Cancer research.

[32]  T. Silveira,et al.  A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.